利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

9 条记录 (耗时 0.011 秒)

    Liposome for liver-specific delivery and release of therapeutic nucleic acids or drugs
    4.
    发明授权
    Liposome for liver-specific delivery and release of therapeutic nucleic acids or drugs 有权
    用于肝特异性递送和释放治疗性核酸或药物的脂质体

    公开(公告)号：US08318199B2

    公开(公告)日：2012-11-27

    申请号：US12791600

    申请日：2010-06-01

    申请人： Meehyein Kim ,  Soo In Kim ,  Duckhyang Shin ,  Mahnhoon Park

    发明人： Meehyein Kim ,  Soo In Kim ,  Duckhyang Shin ,  Mahnhoon Park

    IPC分类号： A61K9/127 ,  C12N15/88 ,  A61K48/00

    CPC分类号： A61K31/7088 ,  A61K9/1272

    摘要： Disclosed herein is a composite of a nanoscale particle size. The composite is able to specifically deliver therapeutic agents such as therapeutic nucleic acids or drugs to the liver and selectively release them into hepatic cells to manifest potent therapeutic effects of the therapeutic agents. The composite may be comprised of an apolipoprotein A-1 and a liposome-forming material. A composition containing the composite and a pharmaceutically acceptable carrier is disclosed.

    摘要翻译： 本文公开了纳米级粒度的复合材料。 复合材料能够将治疗剂例如治疗性核酸或药物特异性递送至肝脏并选择性地将其释放到肝细胞中以显示治疗剂的有效治疗作用。 复合材料可以由载脂蛋白A-1和脂质体形成材料组成。 公开了含有该复合物和药学上可接受的载体的组合物。

    Supertype Epitopes, Oligonucleotides Coding The Same Which Induce Effective Ctl Response Against Hcv And The Use Thereof
    6.
    发明申请
    Supertype Epitopes, Oligonucleotides Coding The Same Which Induce Effective Ctl Response Against Hcv And The Use Thereof 审中-公开
    超型表型，编码与Hcv有效Ctl反应相同的寡核苷酸及其用途

    公开(公告)号：US20080112977A1

    公开(公告)日：2008-05-15

    申请号：US11571598

    申请日：2005-07-04

    申请人： Yu Kyeong Hwang ,  Nam Kyung Kim ,  Jung Min Park ,  Okjae Lim ,  Mahnhoon Park

    发明人： Yu Kyeong Hwang ,  Nam Kyung Kim ,  Jung Min Park ,  Okjae Lim ,  Mahnhoon Park

    IPC分类号： A61K39/29 ,  A61K31/7052 ,  A61P31/12 ,  C07H21/00 ,  C12N15/63

    CPC分类号： C07K14/005 ,  A61K39/12 ,  A61K39/29 ,  A61K2039/53 ,  A61K2039/55522 ,  C12N2770/24222 ,  C12N2770/24234

    摘要： The present invention relates to a supertype epitope which effectively induce a cell-mediated immune response and its use, specifically, a supertype epitope which effectively induce the cytotoxic T lymphocytes specific to HCV and come from conservative region of a HCV polyprotein, an expression vector comprising the oligonucleotide coding the said supertype epitope, a vaccine composition comprising the said supertype epitope or the said expression vector and its use for treatment of hepatitis C. The HCV supertype epitope of the present can be applied to various individuals because it binds to various HLA molecule and can induce antigen-specific immune response, be used to develop therapeutics for hepatitis C by virus hepatitis C and the vaccines for a liver disease related to that as a strong and effective tool, the expression vector comprising the oligonucleotide coding a HCV supertype epitope and the DNA vaccine comprising it can be used as a strong and effective tool for immune response suppressed hepatitis and liver disease related to that.

    摘要翻译： 本发明涉及有效诱导细胞介导的免疫应答的超型表位及其用途，特别是有效诱导HCV特异性并来自HCV多蛋白保守区的细胞毒性T淋巴细胞的超型表位，包含 编码所述超型表位的寡核苷酸，包含所述超型表位或所述表达载体的疫苗组合物及其用于治疗丙型肝炎的用途。本发明的HCV超型表位可以应用于各种个体，因为它结合各种HLA分子 并且可以诱导抗原特异性免疫应答，用于通过病毒丙型肝炎开发用于丙型肝炎的治疗剂和与其相关的肝病疫苗作为强有力的工具，所述表达载体包含编码HCV超型表位的寡核苷酸和 包含它的DNA疫苗可以用作免疫的强有力的有效工具 与此相关的肝炎和肝脏疾病。

    Small Interfering RNA Specific For HCV And Therapeutic Agent For Hepatitis C Comprising The Same
    9.
    发明申请
    Small Interfering RNA Specific For HCV And Therapeutic Agent For Hepatitis C Comprising The Same 审中-公开
    丙型肝炎病毒的特异性小干扰RNA和丙型肝炎的治疗剂

    公开(公告)号：US20090318531A1

    公开(公告)日：2009-12-24

    申请号：US11915975

    申请日：2006-05-30

    申请人： Meehyein Kim ,  Duckhyang Shin ,  Mahnhoon Park ,  Soo In Kim

    发明人： Meehyein Kim ,  Duckhyang Shin ,  Mahnhoon Park ,  Soo In Kim

    IPC分类号： A61K48/00 ,  C07H21/02 ,  C12N15/63

    CPC分类号： C12N15/1131 ,  C12N2310/111 ,  C12N2310/14 ,  C12N2310/53

    摘要： The present invention relates to a therapeutic reagent for hepatitis C comprising HCV specific short interfering RNA (siRNA) as an effective ingredient. The siRNA of the invention is a double-stranded RNA specific for the nucleotide sequence of HCV which induces viral RNA degradation in mammalian cells and thereby inhibits HCV protein expression and replication. The method of the invention, which includes the step of administrating the synthetic siRNA or a DNA vector encoding the RNA, is thus effective for the treatment of HCV carrier by inhibiting HCV gene expression and replication.

    摘要翻译： 本发明涉及包含HCV特异性短干扰RNA（siRNA）作为有效成分的丙型肝炎治疗试剂。 本发明的siRNA是HCV的核苷酸序列特异性的双链RNA，其在哺乳动物细胞中诱导病毒RNA降解，从而抑制HCV蛋白的表达和复制。 包括给予合成siRNA或编码RNA的DNA载体的步骤的本发明的方法因此通过抑制HCV基因表达和复制而对HCV载体的治疗是有效的。